She Made DNA Tests a Consumer Product
She co‑founded 23andMe. It reached a $6 billion value. It later filed for bankruptcy. She bought it back.
Anne Wojcicki grew up on a university campus.
She was born in Palo Alto, California, on July 28, 1973.
She is the youngest of three sisters.
Her parents taught her to ask questions.
Early Life and Family
Anne’s mother, Esther, worked in education and journalism.
Her father, Stanley, taught physics at Stanford.
The family lived on the Stanford campus.
They valued learning and curiosity.
School Years
Anne attended Gunn High School in Palo Alto.
She edited the school newspaper.
After high school she went to Yale University.
She earned a B.S. in biology in 1996.
She played varsity women’s ice hockey at Yale.
First Jobs in Science
After Yale she worked as a molecular biology researcher.
She spent time at the National Institutes of Health.
She also worked at the University of California, San Diego.
These labs taught her how DNA works.
Wall Street and Investment Career
Anne moved to finance after her lab work.
She spent about ten years as a healthcare analyst.
She worked for Investor AB, Ardsley Partners, Andor Capital, and Passport Capital.
She learned how to value biotech companies.
Founding 23andMe
In 2006 Anne started 23andMe.
She founded it with Linda Avey and Paul Cusenza.
The goal was to let people see their own genetic data.
The company used high‑profile stunts to get attention.
The FDA sent a warning letter in November 2013.
It ordered the company to stop marketing health reports.
Anne chose to work with the agency instead of shutting down.
She ran studies that showed customers could understand their results.
In 2015 the FDA gave the first authorizations for direct‑to‑consumer health reports.
23andMe grew to over 14 million customers.
The company went public in 2021 with a $3.5 billion SPAC deal.
It bought Lemonaid Health for $400 million.
Revenue reached $299 million in fiscal year 2023, but profit remained low.
The stock fell 95 percent from its $6 billion peak.
In March 2025 the company filed for Chapter 11 bankruptcy.
Anne resigned as CEO at that time.
She created the TTAM Research Institute.
The nonprofit bought the company’s assets for $305 million.
Now she leads the 23andMe Research Institute.
Challenges and Controversies
Anne held about 49 percent of voting power in the company.
That gave her near‑total control.
In 2024 all seven independent directors quit.
The board could not agree on a plan to take the company private.
A data breach in 2023 exposed information of nearly 7 million customers.
More than 30 lawsuits followed.
The FDA dispute in 2013 halted health‑risk reports for years.
The business model relied on one‑time DNA kit sales.
Repeat purchases were low.
A costly move into drug development burned cash.
Philanthropy and Personal Interests
Anne joined The Giving Pledge in 2022.
She co‑founded the Brin Wojcicki Foundation.
She also started the Anne Wojcicki Foundation.
She enjoys fitness and longevity research.
She likes tracing her family lineage.
Quotes
If you think something is stupid, then change it.
The worst thing you can do in life is whine about what you can’t change.
Anne Wojcicki’s story shows how science, finance, and perseverance can reshape health.
It also shows how regulation and market pressure can test a founder’s resolve.
Her next chapter is building a nonprofit that keeps DNA testing open to everyone.
Founding Story
Anne Wojcicki started 23andMe in 2006.
She wanted people to own their DNA data.
She worked with Linda Avey and Paul Cusenza.
The goal was to shift health care toward wellness.
She used her biotech investment background.
First Customers & Product
The first kits let users spit into a tube.
Customers received ancestry and health reports.
The service was sold directly online.
Early buzz came from celebrity spit parties.
The product opened a new market for DNA testing.
Early Struggles
Sales fell after the initial hype.
Medical experts questioned the test accuracy.
The FDA sent a warning letter in November 2013.
The company had to stop health‑risk reports.
Anne chose to work with the agency instead of quitting.
Key Turning Points
In 2015 the FDA gave the first authorizations for health reports.
The authorizations created a new path for direct‑to‑consumer testing.
23andMe began large‑scale research collaborations.
The company added drug‑development projects.
Growth & Funding
By 2023 the firm had over 14 million genotyped customers.
Revenue reached $299 million in fiscal year 2023.
The company raised billions from investors over a decade.
It kept a dual‑class share structure giving Anne about 49 % voting power.
IPO, Acquisitions & Later Events
In 2021 23andMe went public via a $3.5 billion SPAC merger with VG Acquisition Corp.
The same year it bought telehealth firm Lemonaid Health for $400 million.
Revenue growth slowed and losses grew.
The stock fell 95 % from its $6 billion peak.
In March 2025 the company filed Chapter 11 bankruptcy.
Anne resigned as CEO.
Her nonprofit TTAM Research Institute bought the assets for $305 million.
The new nonprofit now runs 23andMe as a research organization.
Anne Wojcicki remains a pioneer in personalized health.
She focuses on open‑source medical research now.
She also supports AI health startups as an operating partner at Treehub.
Her story shows how a bold idea can rise, fall, and be rebuilt.
Setbacks
The FDA sent a warning in November 2013. It ordered 23andMe to stop health‑risk reports. Wojcicki obeyed. She worked with the agency to fix the problem. The company earned its first FDA authorizations in 2015.
In 2023 a data breach exposed the genetic data of nearly 7 million users. The breach led to more than 30 lawsuits. It hurt the company’s reputation.
The business lost money for years. Stock value fell from $6 billion to pennies. In March 2025 the firm filed Chapter 11 bankruptcy.
Criticism and Controversies
Wojcicki held about 49 % of voting power. The dual‑class share structure gave her near total control. In 2024 all seven independent directors quit at once. They could not agree on her plan to take the company private.
The 2023 breach raised privacy worries. Customers feared misuse of their DNA.
Critics said the business model relied on one‑time kit sales. They noted the costly move into drug development. The move burned cash and did not produce a product.
Recent Changes
After the 2025 bankruptcy, Wojcicki created the TTAM Research Institute. The nonprofit bought 23andMe’s assets for $305 million. She now runs the 23andMe Research Institute. The focus is on direct‑to‑consumer testing and open‑source research.
In April 2026 she joined Treehub as an operating partner. She works with investors and academics to help early‑stage AI and health startups.
Where They Are Now in 2026
Wojcicki leads the 23andMe Research Institute. The nonprofit runs the DNA testing service. It also supports large‑scale medical studies.
She remains active in philanthropy. She is part of The Giving Pledge. She also runs the Anne Wojcicki Foundation.
Her lifestyle stays practical. She prefers efficiency over luxury.
Why the story matters
The rise and fall show how bold ideas can clash with regulation.
The data breach reminds us that privacy is fragile.
Governance rules matter when one person holds too much power.
Rescuing a bankrupt firm shows that nonprofit models can revive tech.
The lesson is clear: innovation needs oversight, ethics, and resilience.
DNA can change lives to but only if we protect it.
The Record
Birth: July 28 1973, Palo Alto, CA
Education: B.S. Biology, Yale 1996
Founded: 23andMe, 2006
FDA clearance: 2015 for health reports
Bankruptcy: March 2025
Nonprofit purchase: 2025, TTAM Research Institute
Current role: Head of 23andMe Research Institute, Treehub operating partner (2026)
Timeline
1973 to Born in Palo Alto, CA.
1996 to Graduated Yale with a biology degree.
2006 to Co‑founded 23andMe.
2013 to FDA warning letter issued.
2015 to First FDA authorizations for health reports.
2021 to Went public via SPAC merger.
2023 to Major data breach affecting millions.
2025 to Company filed Chapter 11; Wojcicki resigned as CEO.
2025 to TTAM Research Institute bought 23andMe assets.
2026 to Leads 23andMe Research Institute and joins Treehub.